局部前列腺癌焦点治疗后肿瘤学结局与病灶位置的关系:HIFU与冷冻治疗对比
本研究纳入2009至2018年间在单中心接受HIFU或冷冻治疗的274例局限性前列腺癌患者,评估病灶位置对焦点治疗后肿瘤学结局的影响。中位随访51个月,39%接受至少一次额外治疗,31%接受根治性治疗;36个月时基底、中部和尖部病灶的免于额外治疗生存率分别为71%、75%和69%(p=0.7)。多因素分析显示病灶位置与额外治疗或根治性治疗风险无显著相关(均p>0.4),倾向性评分匹配后HIFU与冷冻治疗按病灶位置的额外治疗率无差异。
要点
- 病灶位置(基底、中部、尖部)对焦点治疗后额外治疗率无显著影响(p=0.7)。
- 尖部病灶不应被视为焦点治疗的排除标准。
- HIFU与冷冻治疗在不同病灶位置的中期肿瘤学结果相似。
核心结论
- 前列腺癌病灶位置对焦点治疗后失败率无显著影响。
- 尖部病灶的存在不应视为焦点治疗的排除标准。
- 无论病灶位置如何,HIFU与冷冻治疗的中期肿瘤学结果相似。
研究设计与样本
- 回顾性队列研究,纳入2009至2018年间单中心接受焦点治疗的274例局限性前列腺癌患者。
- 166例接受HIFU,108例接受冷冻治疗。
- 采用Kaplan-Meier法进行生存分析,倾向性评分匹配比较HIFU与冷冻治疗。
主要发现
- 中位随访51个月,39%(106例)接受至少一次额外治疗,31%(85例)接受根治性治疗。
- 36个月时基底、中部和尖部病灶的免于额外治疗生存率分别为71%、75%和69%(p=0.7)。
- 多因素logistic回归显示病灶位置与额外治疗或根治性治疗风险无显著相关(均p>0.4)。
- 倾向性评分匹配后,按病灶位置比较HIFU与冷冻治疗的额外治疗率无差异。
关键数值与推荐
- 36个月免于额外治疗生存率:基底病灶71%,中部病灶75%,尖部病灶69%(p=0.7)。
- 病灶位置与额外治疗或根治性治疗风险的多因素分析均p>0.4。
临床怎么用
- 尖部病灶不应作为焦点治疗的排除标准。
- HIFU和冷冻治疗均可用于不同位置病灶,中期肿瘤学结果相似。
局限性
- 回顾性单中心研究,样本量有限(274例)。
- 中位随访51个月,仅反映中期结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We assessed whether prostate cancer (PCa) location might affect oncologic outcomes after focal therapy (FT) for PCa. MATERIALS AND METHODS: We identified 274 men receiving FT for PCa using either high intensity focused ultrasound (HIFU) or cryotherapy at a high volume center between 2009 and 2018. Survival analyses using Kaplan-Meier method were used to assess any additional treatment and radical treatment rates according to PCa location. Propensity-score match analysis was used to compare oncologic outcomes of HIFU vs cryotherapy according to PCa location. Covariates were prostate specific antigen, clinical stage, prostate volume, Gleason score, maximum cancer core length, percentage of positive cores and treatment modality. RESULTS: A total of 166 and 108 men received FT with HIFU and cryotherapy, respectively. Overall, 39% (106) and 31% (85) received at least an additional treatment and a radical treatment after FT, respectively, with a median followup of 51 months. At 36 months' followup, the rates of any additional treatment-free survival were 71%, 75%, and 69% for patients with basal, mid-prostate and apical disease, respectively (p=0.7). At multivariable logistic regression analysis, PCa location was not significantly associated with higher risk of either any additional treatment or radical treatment (all p >0.4). After matching, there was no difference between HIFU vs cryotherapy in terms of any additional treatment rates according to PCa location. CONCLUSIONS: The PCa location does not significantly affect the rate of failure after FT. The presence of an apical lesion should not be considered an exclusion criteria for FT. Both HIFU and cryotherapy likely achieve similar medium-term oncologic results regardless of PCa location.
引用
- Stabile A, Sanchez-Salas R, Tourinho-Barbosa R, et al. Association between Lesion Location and Oncologic Outcomes after Focal Therapy for Localized Prostate Cancer Using Either High Intensity Focused Ultrasound or Cryotherapy. J Urol. 2021. PMID: 33890485. doi:10.1097/JU.0000000000001787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。